ABT vs PG: How Abbott Laboratories and Procter & Gamble Compare (2026)
Last updated July 2026
Short answer
PG is the larger of the two ($337.32B market cap): the incumbent the market prices for continued execution (19.50x forward earnings, beta 0.38). ABT is the smaller challenger ($190.52B), priced similarly on forward earnings (18.04x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ABT vs PG: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABT | PG | What it tells you |
|---|---|---|---|
| Market cap | $190.52B | $337.32B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 18.04 | 19.50 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 35.40 | 21.21 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.61 | 0.38 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 49% of range | 24% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.66 | 6.28 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ABT and PG affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABT and PG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABT and PG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Abbott Laboratories (ABT) do?
Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Medical Devices, the largest segment at roughly $21.4 billion in 2025 revenue, includes the FreeStyle Libre family of continuous glucose monitors, structural heart products (Navitor, TriClip), electrophysiology systems (AVEIR leadless pacemaker), vascular devices, and heart-failure technologies. Diagnostics contributes roughly $8.9 billion, Nutrition roughly $8.5 billion (anchored by Similac infant formula and Ensure adult nutrition), and Established Pharmaceuticals roughly $5.5 billion in branded generics sold primarily in emerging markets.
What does Procter & Gamble (PG) do?
Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. Its portfolio is organized into segments spanning fabric and home care (Tide, Ariel, Downy, Dawn, Febreze), baby, feminine, and family care (Pampers, Always, Bounty, Charmin), beauty (Olay, Pantene, Head & Shoulders, SK-II), grooming (Gillette, Venus), and health care (Crest, Oral-B, Vicks, Metamucil). P&G makes money selling these branded products through retailers, e-commerce, and other channels worldwide, relying on scale, marketing, and continual product innovation to command premium pricing and shelf space. The company deliberately pruned its portfolio over the past decade to focus on a smaller set of large, profitable, daily-use categories. Founded in 1837 and headquartered in Cincinnati, Ohio, P&G is a classic defensive blue chip and a Dividend King, prized for steady cash flow, pricing power, and an exceptionally long record of dividend increases.
ABT vs PG: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ABT drivers: FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum.
- PG drivers: Brand strength and pricing power; Defensive, recurring demand.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. For PG, p&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives.
ABT or PG: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABT if you believe its drivers more; PG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABT and PG guides.
ABT vs PG: the full fundamentals
ABT. ABT's trailing GAAP P/E of roughly 26x sits below its own 3-year, 5-year, and 10-year historical averages, and is modestly above the Medical Devices and Instruments industry median of roughly 25x, suggesting the market has re-rated the stock from COVID-era growth-premium levels while still assigning a quality multiple. Revenue growth has remained consistently positive in the 5-7% range even as GAAP EPS was pressured in FY2025 by a year-over-year comparison that included elevated one-time items. The FY2026 adjusted EPS guidance of $5.38-$5.58 implies a forward adjusted P/E in the high-teens to low-twenties range at recent share prices, which analysts broadly describe as modestly discounted relative to fundamental fair value estimates.
PG. P&G is a high-margin, cash-rich consumer-staples leader that commands a premium valuation for its brand strength, defensiveness, and unmatched dividend record. The financial profile is steady rather than fast-growing: modest organic growth, reliable margins, and consistent capital return funded by very strong free cash flow.
Headline figures (approximate, 2026-06-27 (TTM through Q1 2026; share price data as of June 26, 2026)): ABT shows revenue (ttm) ~$45.1 billion, revenue (fy 2025) ~$44.3 billion (+5.7% YoY), net income (fy 2025) ~$6.5 billion, net profit margin (fy 2025) ~14.7%; PG shows revenue (ttm) ~$84 billion, operating margin ~24%, net margin ~18%, free cash flow ~$15+ billion annually.
The bottom line: ABT vs PG
ABT and PG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABT and PG exposure against your real portfolio. It is not an investment adviser.
Investing in Abbott Laboratories with AI
Connect the broker you already use and ask Walnut's AI how ABT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ABT and PG?
+
Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABT or PG the better stock?
+
Neither is universally better. PG is the larger incumbent; ABT is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABT or PG?
+
On forward P/E (as of July 2026), ABT trades at 18.04x and PG at 19.50x, so ABT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABT and PG?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABT vs PG?
+
ABT: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases still pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Integration of the approximately $21 billion Exact Sciences acquisition introduces execution risk, short-term EPS dilution, and elevated SGA costs that compressed Q1 2026 operating earnings year over year. Foreign exchange headwinds have consistently shaved 2-3 percentage points off reported international revenue growth, and any meaningful dollar strengthening would pressure reported results disproportionately given Abbott's broad non-US exposure. Competitive disruption in continuous glucose monitoring from DexCom and emerging players, along with pricing pressure from government payers and the Inflation Reduction Act, represent structural long-term headwinds. PG: P&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives. A large share of sales comes from outside the US, exposing earnings to a strong dollar and emerging-market currency swings. Input-cost inflation (commodities, energy, transportation) can pressure margins. Private-label competition and shifting retailer dynamics, including the bargaining power of large retailers, are persistent threats. The defensive profile also means the stock can lag sharply in strong bull markets, and its premium valuation leaves little room for execution missteps.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABT or PG; figures are approximate and dated (as of July 2026). Verify current data before investing.